Loading
Life sciences · Observational Study
ClinicalTrials.gov · September 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07154615). This is a study registration, not published results. Lead sponsor: University of Minnesota. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 150 participants (ESTIMATED). Conditions: Sepsis. Interventions: OTHER: Observational Only. Primary outcome measures: EliSpot - Day 1 , Day 1; EliSpot - Day 4 , Day 4; EliSpot - Day 7 , Day 7; EliSpot - Day 14 , Day 14; EliSpot - Day 21 , Day 21; EliSpot - Day 28 , Day 28; Ex Vivo TNF Production - Day 1 , Day 1; Ex Vivo TNF Production - Day 4 , Day 4; Ex Vivo TNF Production - Day 7 , Day 7; Ex Vivo TNF Production - Day 14 , Day 14; Ex Vivo TNF Production - Day 21 , Day 21; Ex Vivo TNF Production - Day 28 , Day 28; Flow Cytometry of Peripheral Blood Leukocytes - Day 1 , Day 1; Flow Cytometry of Peripheral Blood Leukocytes - Day 4 , Day 4; Flow Cytometry of Peripheral Blood Leukocytes - Day 7 , Day 7; Flow Cytometry of Peripheral Blood Leukocytes - Day 14 , Day 14; Flow Cytometry of Peripheral Blood Leukocytes - Day 21 , Day 21; Flow Cytometry of Peripheral Blood Leukocytes - Day 28 , Day 28; Quantification of Cytokines in Serum - Day 1 , Day 1; Quantification of Cytokines in Serum - Day 4 , Day 4; Quantification of Cytokines in Serum - Day 7 , Day 7; Quantification of Cytokines in Serum - Day 14 , Day 14; Quantification of Cytokines in Serum - Day 21 , Day 21; Quantification of Cytokines in Serum - Day 28 , Day 28; Quantification of Chemokines in Serum - Day 1 , Day 1; Quantification of Chemokines in Serum - Day 4 , Day 4; Quantification of Chemokines in Serum - Day 7 , Day 7; Quantification of Chemokines in Serum - Day 14 , Day 14; Quantification of Chemokines in Serum - Day 21 , Day 21; Quantification of Chemokines in Serum - Day 28 , Day 28; Transcriptional Profiling - Day 1 , Day 1; Transcriptional Profiling - Day 4 , Day 4; Transcriptional Profiling - Day 7 , Day 7; Transcriptional Profiling - Day 14 , Day 14; Transcriptional Profiling - Day 21 , Day 21; Transcriptional Profiling - Day 28 , Day 28; CBC - Day 1 , Day 1; CBC - Day 4 , Day 4; CBC - Day 7 , Day 7; CBC - Day 14 , Day 14; CBC - Day 21 , Day 21; CBC - Day 28 , Day 28. Brief summary: Sepsis leads to sustained immune system dysfunction resulting in increased susceptibility to secondary infection while in the hospital or after discharge. Consequently, many of the \~2 million Americans that develop sepsis every year will end up back in the ICU, weeks and months later. The objective of this study is to define the cellular and molecular mechanisms driving the dysfunction and reprogramming of T cells and B cells that mediate cellular and humoral immunity using a combination of phenotypic, functional, genomic, and metabolomic assays.